µ²ºc¦¡ |
|
Neratinib maleate (E)-N-{4-[3-chloro-4-(pyridin-2-yl methoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl}-4-(dimethylamino)but-2-enamide maleate
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
Neratinib¬O¤@ºØ²ÓM¤º¿E酶§í¨î¾¯¡A·|»Pªí¥Ö¥Íªø¦]¤l¨üÅé(EGFR)¡BHER2»PHER4§Î¦¨¤£¥i°fªº³sµ²¡C¦b¥ÍÅé¥~¡Aneratinib·|°§CEGFR»PHER2¦ÛÁC»Ä¤Æ¡B¤U´åªºMAPK»PAKT°T®§¶Ç»¼¸ô®|¡A¨ÃÃÒ¹ê¹ïªí²{EGFR©M/©ÎHER2ªºÀù²ÓM®è¨ã§Ü¸~½F¬¡©Ê¡CNeratinib¤HÅé¥NÁª«M3¡BM6¡BM7»PM11¦b¥ÍÅé¥~·|§í¨îEGFR¡BHER2»PHER4ªº¬¡©Ê¡C¦b¥ÍÅ餺¡A¤fªA§ë¤©neratinib¦b¸~½F²ÓM®èªí²{HER2»PEGFRªº¤p¹«²§ºØ²¾´Ó¼Ò«¬¤¤·|§í¨î¸~½F¥Íªø¡C
|
¾AÀ³¯g |
|
1. ¦´Á¨ÅÀùªº±j¤Æ»²§U©ÊªvÀø¡G NERLYNX³æ¤@Àøªk¡A¾A¥Î©ó±w¦³¤HÃþªí¥Ö¥Íªø¦]¤l¨üÅé2 (HER2) ¶§©Ê¤§¦´Á¨ÅÀù¦¨¤H¯f¤H¡A§@¬°¦b§ttrastuzumab»²§U©ÊÀøªk¤§«áªº±j¤Æ»²§U©ÊªvÀø¡C 2. ±ß´Á©ÎÂಾ©Ê¨ÅÀù¡GNERLYNX»Pcapecitabine¦X¨ÖÀøªk¡A¾A¥Î©ó´¿¸g±µ¨ü¨âºØ¥H¤W§ÜHER2Àøµ{ªvÀøÂಾ©Ê¨ÅÀù¤§±ß´Á©ÎÂಾ©ÊHER2¶§©Ê¨ÅÀù¦¨¤H¯f¤H¡C
|
¥Îªk¥Î¶q |
|
¤îÂm¹w¨¾ªvÀø ©ó³Ìªì 56 ¤ÑªvÀø´Á¶¡µ¹¤©¤îÂm¹w¨¾ªvÀø¡A¥BÀH²Ä¤@¾¯ NERLYNX ®i¶}ªvÀø¡C«ü¥Ü¯f¤H¨Ì¥é³æªí 1 ©Ò¥ÜªA¥Î loperamide¡A³vº¥½Õ¾ã loperamide ¾¯¶q¦Ü¨C¤é 1 ¦Ü 2 ¦¸±Æ«K¡C ¦´Á¨ÅÀùªº±j¤Æ»²§U©ÊªvÀø NERLYNXªº«Øij¾¯¶q¬°¨C¤é¤@¦¸¡A¤fªA240 mg (¤»¿õ)¡AÀHÀ\ªA¥Î¡A«ùÄòªvÀøª½¦Ü¯e¯f´_µo©Î¬°´Á³Ìªø1¦~¡C ±ß´Á©ÎÂಾ©Ê¨ÅÀù NERLYNX ªº«Øij¾¯¶q¬°¦b 21 ¤Ñ¶g´Áªº²Ä 1-21 ¤Ñ¡A¨C¤é¤@¦¸¡A¤fªA 240mg(¤»¿õ)¡AÀHÀ\ªA¥Î¡F¨Ã¦b 21 ¤Ñ¶g´Áªº 1-14 ¤Ñ¤fªA capecitabine(750mg/m2¡A ¨C¤é¨â¦¸)¡Aª½¨ì¯e¯f´c¤Æ©Î¥X²{¤£¥i±µ¨üªº¬r©Ê¡C «ü¥Ü¯f¤H¨C¤Ñ©ó¤j¬ù¬Û¦Pªº®É¶¡ªA¥Î NERLYNX¡CNERLYNX ¿õ¾¯À³§¹¾ã§]ªA(¤£À³©CÄZ¡B«rÂ_©Î¤ÁÂ_«á§]ªA)¡C Y¯f¤H§Ñ°O¥ÎÃÄ¡A½Ð¤Å¸É¤W¿òº|ªº¾¯¶q¡A¨Ã«ü¥Ü¯f¤HÄ~Äò«ö·Ó¤U¤@¾¯±Æ©wªº¨C¤é¾¯¶qªA¥Î NERLYNX
|
ÃİʤO¾Ç |
|
§l¦¬ Neratinib»P¥Dn¬¡©Ê¥NÁª«M3¡BM6»PM7©ó¤fªA§ëÃÄ«á2¦Ü8¤p®É¤§¶¡¹F¨ì³Ì°ª¿@«×¡C ¤À§G ¦b¯f¤H¤¤¡A§ë¤©¦h¾¯NERLYNX«á¡Aéwª¬ºA¤UªºÀÀ¦ü¤À§GÅé¿n¥§¡È(%CV) (Vss/F)¬°6433 (19%) L¡C¦bÅé¥~¸ÕÅç¡A¤HÃþ¦å¼ß¤¤neratinibªº³J¥Õ½èµ²¦X²v°ª©ó99%¡A¥B»P¿@«×µLÃö¡CNeratinib¥Dn»P¤HÃþ¦å²M¥Õ³J¥Õ©M¤HÃþ£\-1»Ä©Ê¿}³J¥Õµ²¦X¡C ¥NÁ Neratinib¥Dn¦b¨xŦ¤¤¥ÑCYP3A4¥NÁ¡A¤Ö³¡¤À¥Ñ§t¶À¯Àªº³æ¥[®ñ酶 (Flavin-containing monooxygenase¡FFMO)¥NÁ¡C ±Æªn ¤fªA§ë¤©200 mg (®Öã«Øij¾¯¶qªº0.83¿)©ñ®g¼Ð©wªºneratinib¤fªA¾¯«¬«á¡AÁT«K±Æªn¦ûÁ`¾¯¶q¬ù97.1%¡A¦Ó§¿²G±Æªn¦û1.13%¡C±Æªn©ñ®g¬¡©Êªº61%¦b96¤p®É¤º¦^¦¬¡A¦Ó10¤Ñ«á¦^¦¬98%¡C
|
°Æ§@¥Î |
|
¸¡Âm¡Bäú¤ß¹Ã¦R¡B¸zG¤£¾A¡C
|
¥æ¤¬§@¥Î |
|
1. NERLYNX¥i¯à»P³\¦hÃĪ«²£¥Í¥æ¤¬§@¥Î¡F¦]¦¹¡AÀ³«ü¥Ü¯f¤H¦V¨ä°·±d·ÓÅ@´£¨ÑªÌ³q³ø¥ô¦ó¨ä¥L³B¤èÃĩΫD³B¤èÃĩίóÃÄ»s«~ªº¨Ï¥Î¡C„P 2. NERLYNX¥i¯à»P°G»ÄÃĪ«²£¥Í¥æ¤¬§@¥Î¡C«ü¥Ü¯f¤HÁקK»P½è¤l¬¦§í¨î¾¯(PPI)¨Ö¥Î¡C·í¯f¤H»Ýn°G»ÄÃĪ«®É¡A¨Ï¥ÎH2¨üÅé«ú§Ü¾¯©Î¨î»Ä¾¯¡C«ü¥Ü¯f¤H¨î»Ä¾¯»PNERLYNXµ¹ÃĶ·¶¡¹j¦Ü¤Ö3¤p®É¡A¦Ó¦bªA¥ÎH2¨üÅé«ú§Ü¾¯¦Ü¤Ö2¤p®É«e©Î10¤p®É«á¡A¦AªA¥ÎNERLYNX¡C 3. NERLYNX¥i¯à»P¸²µå¬c²£¥Í¥æ¤¬§@¥Î¡C«ü¥Ü¯f¤HÁקK¦bªA¥ÎNERLYNX®É¹¥Î¸²µå¬c»s«~¡C
|
¸T§Ò |
|
µL¡C
|
¹L¶q³B²z |
|
¨ÃµL¯S©wªº¸Ñ¬r¾¯¡A¦Ó¥H³zªRªvÀøNERLYNX¹L¶qªº®Ä¯q¥Ø«e¤£©ú¡Cµo¥ÍÃĪ«¹L¶q®É¡AÀ³¼È°±§ëÃĨñĨú¤@¯ë©Êªº¤ä«ù±¹¬I¡C
¦bÁ{§É¸ÕÅ籡ªp¤¤¡A¤Ö¼Æ¯f¤H³q³øÃĪ«¹L¶q¡C³o¨Ç¯f¤Hµo¥Íªº¤£¨}¤ÏÀ³¬°¸¡Âm¡Bäú¤ß¡B¹Ã¦R»P²æ¤ô¡CG¸z¯e±w(¸¡Âm¡B¸¡µh¡Bäú¤ß»P¹Ã¦R)ªºÀW²v»PÄY«µ{«×ÅãµM»P¾¯¶q¬ÛÃö¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
Àx¦sNERLYNX©ó«Ç·Å30¢XC¥H¤U¡C
|